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︿Abstract﹀
　FK506 binding proteins (FKBPs) are a protein family that is the intracellular target of a potent 
immunosuppressive drug, FK506.  An isoform termed FKBP12.6 has been found to be bound with 
the ryanodine receptor 2 (RYR2).  The RYR2 is the major calcium release channel (CRC) of the 
sarcoplasmic reticulum of cardiac muscle, and is also expressed in a variety of cell types.  However, 
the function of the FKBP12.6 bound to the RYR2 is controversial.  To use as a probe to study the 
role of FKBP12.6 bound to the RYR2, we prepared monoclonal antibodies that are genuinely specific 
for FKBP12.6.  Lymph node cells from mice immunized with recombinant His-FKBP12.6 were fused 
with a myeloma cell line, and the resulting hybridomas were screened by ELISA for production of 
a relevant antibody.  Two monoclonal hybridomas (1B4/G3 and 1C2/G10) that produce antibodies 
that react only with FKBP12.6 but not FKBP12, a closely related isoform, were established.  The 
monoclonal 1B4/G3 antibody was applicable to detect native FKBP12.6 by Western blotting in 
cardiac sarcoplasmic reticulum fraction enriched in the RYR2-FKBP12.6 complex.  These results 
suggested that our monoclonal antibodies are candidates to be useful probes to elucidate the 
physiological role of FKBP12.6.
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Introduction
　FK506 binding proteins (FKBPs) are a 
protein family, most of whose members bind 
to a powerful immunosuppressive drug, 
FK506, and show peptidyl-prolyl cis/trans 
isomerase (PPIase) activity.  Among numbers 
of FKBPs, the most abundant isoform termed 
FKBP12 is the sole isoform responsible for 
mediating the immunosuppressive actions 
of the drug in vivo.  The PPIase activity of 
FKBPs is inhibited by FK5061). However, 
inhibition of the PPIase activity of FKBP12 
is unrelated to the immunosuppressive action 
of FK506.  Instead, the immunosuppressive 
action of the drug results from the inhibition 
of calcineurin, a calmodulin-dependent/Ca2+-
activated protein phosphatase.  During T cell 
activation, calcineurin dephosphorylates the 
cytosolic component of NF-AT that leads this 
key transcription factor to be translocated to 
the nucleus, which in turn triggers IL-2 gene 
expression.  The FKBP12·FK506 complex 
inhibits calcineurin to block T cell activation, 
which then results in immunosuppression. 
However, neither FKBP12 nor FK506 alone 
interact with calcineurin; it is not until forming 
a complex with FK506 that FKBP12 interacts 
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with and inhibits calcineurin2).  Furthermore, 
FKBP12 is expressed, not only in T cells, but 
in most, if not all, cell types.  Thus, FKBP12 
is a mere bystander protein during T cell 
activation that becomes involved in preventing 
activation after it binds FK506.  To date, the 
most well understood physiological function of 
FKBPs is their interaction with the ryanodine 
receptors.
　The ryanodine receptors (RYRs) are a 
protein family that function as an intracellular 
calcium release channel (CRC) located on 
the endo(sarco)plasmic reticulum membrane. 
The RYRs are by far the largest ion channel 
protein complexes that exist as homotetramers 
thereby exhibiting 4-fold symmetry.  There 
are three types, RYR1, RYR2 and RYR3. 
Although the RYRs are expressed in many cell 
types, they are expressed at a very high level, 
especially in skeletal and cardiac muscles. 
The RYR1 and RYR2 of the sarcoplasmic 
reticulum (SR) of skeletal and cardiac muscle, 
respectively, play a crucial role in excitation-
contraction coupling of these striated muscle3).
　The FKBP isoforms that have been shown 
to interact with the RYRs are FKBP12 and 
FKBP12.6, an isoform structurally closely 
related to FKBP12.  FKBP12 is tightly bound 
to4) and modulates5)-10) the CRC/RYR1 of 
skeletal muscle sarcoplasmic reticulum (SR) in 
vivo, although in vitro experiments have shown 
that the RYR1 is capable of binding with both 
FKBP12 and FKBP12.611), 12). It was first found 
that the CRC isolated from rabbit skeletal 
muscle terminal cisternae (TC) of SR is tightly 
associated with FKBP124) in a stoichiometry of 
four FKBP12 per one RYR15).  Subsequently, 
the tight association between the RYR1 and 
FKBP12 in skeletal muscle TC was found 
to be common to each of the five classes of 
vertebrates, i.e. mammals, birds, reptiles, fish, 
and amphibians13).  Thus, the native CRC of 
skeletal muscle SR is a heterooligomer with 
a structural formula of (RYR1 protomer)4 
(FKBP12)4. In contrast to the RYR1, the RYR2 
has been shown to have a binding preference 
to FKBP12.6 over FKBP1211), 14). Particularly, 
canine cardiac RYR2 showed a 500~1,000 fold 
higher affinity for FKBP12.6 compared to 
FKBP1211). Likewise the RYR1, one mole of 
the RYR2 channel also has four moles of the 
binding sites for FKBP.
　FKBP bound  t o  the  RYR i s  gen t ly 
dissociated when the SR fraction or purified 
channel is treated with FK5065),11). Extensive 
in vitro studies to elucidate the function(s) 
of FKBP12 and/or FKBP12.6 bound to the 
RYR1 or RYR2 have been carried out using 
FKBP-stripped RYRs.  In studies comparing 
the function of the native RYR1 with FKBP-
stripped RYR1, it has been shown that 
FKBP12 bound to the RYR1 modulates the 
channel activity by stabilizing the closed 
conformation of the channel5),7),10). It has also 
been proposed that FKBP12 synchronizes the 
gating of neighboring RYR1 channels (coupled 
gating)15), 16). In an in situ study employing 
skinned skeletal muscle fiber, E-C coupling 
was impaired upon depletion of bound FKBP 
from the RYR1 by treatment of FK506 or 
rapamycin17). Thus, FKBP12 seems to have 
established its status as an integral component 
of the RYR1 that modulates the channel 
function.  In contrast to the FKBP12 bound 
to the RYR1, the physiological role of the 
FKBP12.6 bound to the RYR2, at present, 
remains unclear and controversial.  In in 
vitro studies comparing the function of the 
native RYR2 with FKBP-stripped RYR2, 
some research groups have reported similar 
effects of FKBP12.6 on the RYR2 as FKBP12 
on the RYR118), 19), while some have shown 
there are no similar effects11), 20). Interestingly, 
FKBP12.6-knockout mice show abnormalities 
in heart function21), 22), although results from 
the two laboratories differ in detail.  Moreover, 
although controversial, Marks and colleagues 
have proposed that removal of FKBP12.6 from 
the RYR2 is involved in the mechanism for the 
progression of heart failure23). They raised a 
hypothesis that in the hyperadrenergic state in 
heart failure, protein kinase A is overactivated, 
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resulting in hyperphosphorylation of the 
RYR2, causing FKBP12.6 to dissociate from 
the channel.  Marks’s group insists that this is 
due to the fact that FKBP12.6-depleted RYR2s 
exhibit an abnormally high open probability 
during diastole that in turn allows leakage of 
Ca2+ from the SR; this subsequently reduces 
the Ca2+ that is required to induce contraction 
during systole,  and might also trigger 
ventricular tachycardia.  It is, at present, 
controversial if this hypothesis for heart 
failure is legitimate since both evidence for24), 25) 
and against it has been reported.  Nevertheless, 
in light of these results, FKBP12.6 must be 
implicated in the modulation of the channel 
function of the RYR2.
　To elucidate the role of FKBP12.6 bound to 
the RYR2, probes such as antibodies specific 
for FKBP12.6 would be a powerful tool.  For 
that, in this study, we developed monoclonal 
ant ibodies  that  spec i f ica l ly  recognize 
FKBP12.6, but not FKBP12.
Materials and methods
Recombinant FK506 binding proteins
　Recombinant rabbit FKBP12.6 and human 
FKBP12 tagged with six consecutive His 
residues at the N-terminus (His-FKBP12.6 
and His-FKBP12) were kindly gifted by Dr. 
Yoshiro Chuman, Division of Chemistry, 
Graduate School  of  Science ,  Hokkaido 
University, Sapporo, 060-0810.
Immunization and cell fusion
　To obtain monoclonal antibodies (mAbs) 
against FKBP12.6, recombinant His-FKBP12.6 
protein was used as the immunogen.  It was 
dissolved in phosphate buffered saline (1 mg/ 
mℓ)  and emulsified with an equal volume 
of Freund’s complete adjuvant (Difco, BD, 
Franklin Lakes, NJ). Two female BALB/c 
mice were injected with the emulsion (50 µℓ/
mouse) in the footpad.  Three weeks after 
immunization, the inguinal lymph node cells 
(4 x 107 cells) were fused with P3X63Ag8U.1 
myeloma cells (1 x 107 cells) using polyethylene 
glycol 1500 (Roche Diagnostics).  Fused cells 
were cultured in 96-well plates at 2 x 105 cell/
well in HAT selection medium.  After the 
HAT-resistant cells had grown sufficiently, 
the supernatants were assayed for anti-
FKBP12.6 antibody titer by an enzyme-
linked immunosorbent assay (ELISA) using 
recombinant His-FKBP12.6, and His-FKBP12 
proteins.
Enzyme Linked Immunosorbent Assay (ELISA)
　All the procedures were carried out at 
room temperature.  96-well ELISA plates were 
inoculated with 50 μℓ/well of His-FKBP12.6 or 
His-FKBP12 diluted in 50 mM Na2CO3 at 1 mg/
mℓ, and incubated overnight to immobilize 
the protein.  After three washings with Tris 
buffered saline (TBS, 20 mM Tris-Cl, pH 7.5, 
150 mM NaCl), the plates were incubated with 
0.5% defatted milk in TBS (200μℓ/well) for 1 
hour at room temperature to block non-specific 
binding of immunoglobulin.  After blocking, 
the culture supernatant of hybridomas 
were added to the wells (50 μℓ/well) and 
incubated for 1 hour, then washed six times 
with TBS containing 0.1% Tween 20 (TBST). 
The wells were incubated with 50μℓ of a 
alkaline phosphatase-conjugated donkey anti-
mouse Ig G (Jackson ImmunoResearch) at a 
dilution of 1: 2,500 in TBST containing 0.1% 
defatted milk for 1 hour.  After six washings 
with TBST, immunodetection was performed 
by color development using p-nitro phenyl 
phosphate (1mg/mℓ  in 100mM Tris-Cl, pH 9.5, 
100mM NaCl, 5mg/mℓ MgCl2) as substrate 
reagents. Optical density at 405 nm was 
measured by an automated microtiter plate 
reader (Model 550, Bio-Rad).
Isotyping of the monoclonal antibodies
　The isotypes of monoclonal antibodies 1B4/
G3 and 1C2/G10 were determined by use of the 
Monoclonal Antibody Isotyping Kit (PIERCE) 
following the manufacturer's instructions.
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Western blot analysis
　All the procedures were carried out 
at  room temperature.   SDS-PAGE was 
performed according to Laemmli26) using 
12.5% polyacrylamide gel.  Separated proteins 
were transferred onto PVDF membranes 
(Immobilon-P; Millipore) using a semi-dry 
electrotransblotter (BioCraft) with the buffer 
containing 48 mM Tris, 39 mM glycine, 
0 .0375% SDS, and 10% methanol .   The 
membrane was blocked for 1 hr with TBST 
containing 5% (w/v) defatted milk.  The 
blocked membrane was probed with the anti-
FKBP12.6 mAb.  After washing with TBST, 
the membrane was incubated with goat anti-
mouse Ig G antibody conjugated with alkaline 
phosphatase.  The membrane was washed with 
TBST and immunodetection was performed 
by color development using 5 bromo-4-chloro-
3-indolyl phosphate-toluidine salt/p-nitro-blue 
tetrazolium chloride as substrate reagents.
Results
Establishment of monoclonal hybridomas 
producing antibody specif c for FKBP12.6
　Lymph node cells (4 x 107 cells) of mice 
immunized with His-FKBP12.6 were fused 
with myeloma cell line, and cultured till the 
hybridomas propagated sufficiently.  Then 
the supernatants were screened for their 
immunoreactivity by ELISA.  Supernatants of 
four wells displayed strong immunoreactivity 
against His-FKBP12.6 (Fig. 1, empty bars). 
These supernatants were further tested 
for their immunoreactivity against His-
FKBP12 (Fig. 1, filled bars).  Three of the 
four supernatants (1A10, 1B4 and 1C2) did not 
recognize His-FKBP12, while one did (4A11). 
The supernatants that reacted with His-
FKBP12.6, but not His-FKBP12, should have 
contained the antibody specific for FKBP12.6. 
Cells in two wells (1B4 and 1C2) showed 
good growth, in addition to the specificity for 
FKBP12.6, therefore hybridomas in these wells 
were cloned by limiting dilution.  Finally, 
two independent relevant clones, 1B4/G3 and 
1C2/G10, that retained both good antibody 
productivity and growth were established. 
These two hybridomas were adapted to 
propagate in a serum-free culture medium. 
Hereafter, the antibodies from these two 
hybridomas are referred to as 1B4/G3 and 
1C2/G10 respectively.
Fig. 1 Screening for anti-FKBP12.6 producing wells 
by ELISA. 96 well ELISA plates coated with His-FKBP12.6 
(empty bars) or His-FKBP12 (filled bars) were probed with 
culture supernatants of wells of 96 well culture plates  (50 
μℓ/well).   Representative data obtained  from the wells 
whose supernatants reacted with at least His-FKBP12.6 or 
His-FKBP12.
Fig. 2 Specific detection of FKBP12.6 by monoclonal 
anti-FKBP12.6 antibodies. Western blot analysis probed 
with monoclonal anti-FKBP12.6 mAbs, 1C2/G10 and 1B4/
G3,  and antibody  that  recognizes both His-FKBP12 and 
FKBP12.6, 4A11.   50 ng of His-FKBP12.6 and His-FKBP12 
were separated in each lane.
　Antigen specificity of the mAbs, 1B4/
G3 and 1C2/G10 were further examined by 
Western blot analysis (Fig. 2). Equal amounts 
of His-FKBP12.6 and His-FKBP12 proteins 
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were separated in all the lanes. Bands of His-
FKBP12.6 and His-FKBP12 were both detected 
in the lane probed with 4A11 (Fig. 2), the 
antibody that had been shown to recognize 
both isoforms of FKBP (Fig. 1). In contrast, 
1B4/G3 and 1C2/G10 mAb detected only the 
band of His-FKBP12.6, but not His-FKBP12. 
The results from Western blot analysis (Fig. 2) 
were consistent with those from ELISA (Fig. 1).
Isotyping of the monoclonal antibody specif c for 
FKBP12.6
　Isotypes of mAbs 1B4/G3 and 1C2/G10 were 
determined by an ELISA using a series of 
isotype-specific antibodies (goat anti-mouse Ig 
G1, Ig G2a, Ig G2b, Ig G3, Ig M, and Ig A). As 
shown in Fig. 3, 1B4/G3 (empty bars) reacted 
most prominently with anti-Ig G3, whereas 
1C2/G10 (filled bars) reacted exclusively with 
anti-Ig G2b.
Fig. 3 Isotyping of monoclonal anti FKBP12.6 
antibodies,1B4/G3 (empty bars), and 1C2/G10 (filled 
bars). Experimental procedures were analogous to that in 
Fig. 1, with the exception of secondary antibodies that are 
highly specific  for mouse Ig G1,  Ig G2a,  Ig G2b,  Ig G3,  Ig 
A or Ig M were used instead of the antibody used in Fig 
1 which cannot distinguish precisely  the  isotypes of  the 
immunoglobulins.
Detection of native FKBP12.6 by monoclonal 
antibody
　Cardiac and skeletal muscle SR fractions 
are known to contain detectable amounts 
of FKBP12.6 and FKBP12 respectively 
by Western blot.  To examine if or not 
the monoclonal antibody raised against 
recombinant His-FKBP12.6 recognizes native 
FKBP12.6 as well, Western blot against dog 
cardiac SR was carried out.  To see if the band 
of FKBP12.6 could be detected in ER enriched 
sample from other tissues such as cerebellum, 
cerebrum, liver, and skeletal muscle were also 
examined.  Membranes were probed with 1B4/
G3 mAb.  As shown in Fig. 4, 1B4/G3 detected 
a band of FKBP12.6 in cardiac SR (upper 
panel), as well as the band of His-FKBP12.6 
(lower panel).  FKBP12 in skeletal muscle SR 
was not detected by 1B4/G3.  No FKBP bands 
were detected in cerebellum, cerebrum, and 
liver samples.  A similar result was obtained 
from an experiment using 1C2/G10 mAb (data 
not shown).
Fig. 4 Detection of native FKBP12.6 by 1B4/
G3 mAb. SR or ER  fractions  (5μg protein/lane) were 
separated and Western blot  analysis probed with 1B4/
G3 mAb was  carried  out.   CarM,  cardiac muscle; Cbl, 
cerebellum;  Liv,  Liver;  SkM,  skeletal  muscle;  Cbr, 
cerebrum; His-12.6, His-FKBP12.6; His-12, His-FKBP12.
Discussion
　The goal of the present study was to obtain 
an antibody specific for FKBP12.6, which can 
distinguish FKBP12.6 from another closely 
related isoform, FKBP12.  Both FKBP12.6 
and FKBP12 consist of 108 amino acids.  Since 
homology between their primary structures 
is 85%, it was expected that if an animal is 
immunized with either FKBP12.6 or FKBP12, 
some B cell clone would produce an antibody 
that is truly specific for the immunized isoform, 
while some would produce a general antibody 
that would not only react with the immunized 
isoform, but also crossreact with the other 
one.  Thus, a polyclonal antiserum would be 
a mixture of the isoform-specific and general 
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antibodies that, as a result, recognizes both 
FKBP12.6 and FKBP12.  In fact, a polyclonal 
antiserum raised against a peptide with a 
partial sequence that is specific to FKBP12 
but also 90% identical to the corresponding 
region of FKBP12.6, reacted with both isoform 
(Onoue H., unpublished data). Therefore, we 
decided to raise the anti-FKBP12.6 antibody 
by monoclonal strategy and select the relevant 
clone.  In the course of screening utilizing 
ELISA, three wells were shown to contain 
antibodies that react with His-FKBP12.6, 
but not with His-FKBP12, suggesting the 
hybridomas in these wells (1A10, 1B4 and 1C2) 
were producing  antibodies truly specific for 
FKBP12.6 (Fig. 1).  A hybridoma (4A11) that 
produces an antibody that reacts with both His-
FKBP12.6 and His-FKBP12 was also obtained. 
Although the reason for this is at present 
unclear since we have not investigated further, 
there seem to be two explanations for the fact 
that 4A11 reacted with His-FKBP12 in addition 
to the immunized antigen, His-FKBP12.6, 1) 
the antibody produced by 4A11 reacts with 
both FKBP12.6 and FKBP12,or; 2) reacts with 
the His-tag moiety of the recombinant FKBPs. 
1B4 and 1C2 were cloned, and two independent 
monoclonal hybridomas 1B4/G3 and 1C2/G10 
were established.  The isotypes of 1B4/G3 
mAb and 1C2/G10 mAb were Ig G3 and Ig G2b, 
respectively (Fig. 3).  
　His-FKBP12.6 used as the immunizing 
antigen, differs from native FKBP12.6 in that 
it has six His residues recombinantly added 
to the N-terminus of the native sequence 
of FKBP12.6. Moreover, recombinant His-
FKBP12.6 has not received post-translational 
modification(s), such as phosphoryration, which 
might occur in native-FKBP12.6. The primary 
purpose that we prepare mAbs specific for 
FKBP12.6 is to use them as probes to elucidate 
the role of FKBP12.6-RYR2 interaction. For 
this, it is particularly important that the 
mAbs react with native FKBP12.6 contained 
in biological specimens such as cardiac SR 
fraction. To examine if or not the mAbs 
prepared in the present study recognize native 
FKBP12.6, Western blot against cardiac SR 
fraction was carried out and probed with 1B4/
G3 or 1C2/G10 mAb.  1B4/G3 mAb successfully 
detected the band of FKBP12.6 in cardiac SR 
sample (Fig. 4) but did not detect FKBP12, 
which is abundant in skeletal muscle SR. 
1C2/G10 mAb showed essentially the same 
immunoreactivity as 1B4/G3 (data not shown).
　There would be a number of situations 
that mAb specific for FKBP12.6 serves as 
a powerful probe. The RYR2 is expressed 
in many tissue/cell types, including cardiac 
muscle, cerebellum smooth muscle cells, and 
pancreatic β-cells, although expression levels 
are low except for cardiac muscle. In addition 
to its crucial role in the E-C coupling in the 
heart, the RYR2 is also involved in other 
cellular functions related to intracellular 
calcium signaling, such as fertilization, 
secretion, and apoptosis.  It is of great interest 
whether or not the RYR2 expressed in cells 
other than cardiac muscle also interacts with 
FKBP12.6. For this, it is important to compare 
the localizations of FKBP12.6 with that of the 
RYR2 in such cell types.  FKBP12 is expressed 
in most, if not all, cell types, while FKBP12.6 
is less ubiquitous. Therefore it is necessary to 
use an antibody that can distinguish FKBP12.6 
from FKBP12.  Our monoclonal anti-FKBP12.6 
antibodies are suitable for this purpose since 
they recognized FKBP12.6, but not FKB12 
(Figs. 1, 2, and 4). Although they detected 
FKBP12.6 in cardiac SR, in which the RYR2 
is highly enriched, they could not detect 
FKBP12.6 in the cerebellum sample where the 
RYR2 is expressed in an extremely low level 
compared to the heart.  The reason for this 
could be that; 1) the affinity of our mAb for 
FKBP12.6 was not sufficiently high, or 2) the 
amount of FKBP12.6 was too low in cerebellum 
microsome fraction. Condensation of the 
antibody and/or purification of FKBP12.6 by 
immunoprecipitation might be solutions for 
the problems mentioned above.  Isotypes of the 
two  mAbs, 1B4/G3 and 1C2/G10, were Ig G3 
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and Ig G2b respectively that are convenient 
for immunoprecipitation. Moreover, Ig G 
is an antibody class that is also suitable for 
immunohistochemistry, which might be an 
effective method to study protein localization 
in situ. These facts suggest that our mABs 
specific for FKBP12.6 could be assets for 
clarifying the physiological role of the 
interaction between RYR2 and FKBP12.6 in 
future studies.
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原　著
FKBP12.6に特異的なモノクローナル抗体の作製と特徴づけ
元梅紗央理*、石井　愛子*、大野友峰子*、武田　朋子*、水田　美穂*、
田中　貴絵*、山崎　里紗*、宇高ちひろ*、中野麻衣子*、尾上　　均*　
︿要　旨﹀
　FK506結合タンパク質（FKBP）は、強力な免疫抑制剤であるFK506の細胞内標的となるタンパク質のファミリー
である。これらの中で、FKBP12.6と呼称されるアイソフォームは、リアノジン受容体2（RYR2）と結合すること
が知られている。RYR2は、心筋小胞体の主要な細胞内Ca2+放出チャネルである。また、RYR2は、その他にも種々
の細胞腫で発現している。しかしながら、RYR2にFKBP12.6が結合していることの生理的役割は、明らかでな
い。今回我々は、RYR2に結合しているFKBP12.6の生理的役割を明らかにしていく研究にプローブとして用いる
目的で、FKBP12.6に真に特異的なモノクローナル抗体を作製した。His-FKBP12.6で免役したマウスのリンパ節細
胞をミエローマ細胞株と融合して作製したハイブリドーマ群の中からFKBP12.6に特異的な抗体を産生する細胞を
ELISA法にて選別した。その結果、FKBP12.6は認識し、かつ、FKBP12.6と近縁のアイソフォームであるFKBP12
を認識しないクローン2株（1B4/G3、1C2/G10）樹立した。モノクローナル1B4/G3抗体を用いたWestern blot法に
より、nativeなFKBP12.6をRYR2-FKBP12.6複合体を高濃度で含む画分である心筋小胞体から検出することができ
た。我々のモノクローナル抗体がFKBP12.6の生理的役割を解明していく上でのプローブとして有望であることが、
今回の結果から示唆された。
キーワード：　FKBP12.6、リアノジン受容体、モノクローナル抗体
＊　西南女学院大学栄養学科
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